Hunting of infected boars is being blamed for the spread of African swine fever in Poland, Estonia, Latvia and Lithuania, according to a top European Commission animal health official, who also rebuffed claims the agency isn't doing enough to fight the virus.
Wisconsin-based Pan Genome Systems is looking for up to $2 million in funding to conduct trials for its live attenuated vaccine to combat Johne's disease.
Artes Biotechnology, InstrAction and Q-Biologicals have teamed to develop a virus-like particle vaccine platform for use in veterinary applications.
With the Ebola death toll mounting in West Africa, a Phase I trial of GlaxoSmithKline's experimental vaccine for the disease is underway at the U.S. National Institutes of Health.
Australian nanopatch developer Vaxxas signed on with the World Health Organization this week in an effort to co-opt the company's patch for use with the polio vaccine. The WHO will help fund the research and move it through preclinical and clinical studies as the organization seeks to make polio a thing of the past.
The U.S. Department of Agriculture has given conditional approval for use of Zoetis' vaccine to combat the porcine epidemic diarrhea virus, or PEDv, that has caused havoc in global swine herds, killing an estimated 8 million piglets in the U.S. alone since it was first reported more than a year ago.
Expect more needle-free vaccines to come to market on the heels of the first approval of a needle-free delivery system for the inactivated flu vaccine, market research firm Frost & Sullivan says.
Pfizer's Prevnar 13, the world's best-selling vaccine, scored a big win Wednesday, nabbing a CDC committee nod for universal use in adults over the age of 65. And once payer coverage kicks in, that's a nod that could be worth $2 billion for Pfizer, analysts say--with Merck's Pneumovax getting a boost, too.
Looks like Pfizer's finally getting the vaccines expansion it's been hankering for. The company agreed to pick up Baxter's marketed vaccines portfolio for $635 million, building up its own business as the Illinois healthcare company slims down for a pharma unit spinoff next year.
GlaxoSmithKline is under pressure from not one, but two regulatory bodies to get problems under control at a flu vaccine plant in Canada. After the FDA handed the company a warning letter late last month, Health Canada now says the pharma giant has a month to lay out a plan for resolving issues there.